Adverse events as reason for discontinuation within the first year
| Adalimumab (n=94) No (%) | Infliximab (n=83) No (%) | Etanercept (n=14) No (%) | Total (n=191) No (%) | |
|---|---|---|---|---|
| *Other serious adverse events were dyspnoea, dermatomyositis, reversible leucopenia, and nausea. | ||||
| Infusion reactions | 3 (3) | 12 (14) | 0 (0) | 15 (8) |
| Skin rashes | 1 (1) | 3 (4) | 0 (0) | 4 (2) |
| Infections | 2 (2) | 5 (6) | 0 (0) | 7 (4) |
| Malignancies | 2 (2) | 0 (0) | 0 (0) | 2 (1) |
| Cardiac disease | 3 (3) | 0 (0) | 0 (0) | 3 (2) |
| SLE-like disease | 0 (0) | 2 (2) | 0 (0) | 2 (1) |
| Other* | 0 (0) | 3 (4) | 1 (7) | 4 (2) |
| Total | 11 (12) | 25 (30) | 1 (7) | 37 (19) |